加拿大大型队列1996-2016年HIV耐药纵向趋势
研究分析不列颠哥伦比亚省6543例初治成人HIV蛋白酶-逆转录酶序列,比较1996与2014年获得性耐药(ADR)和传播性耐药(TDR)比例。ADR从39%降至3%(p<0.0001),TDR从12%升至18%(p=0.14)。近期启动cART者ADR罕见,主要见于最低依从性层。
要点
- 1996至2014年ADR比例从39%降至3%,TDR从12%升至18%但无统计学意义。
- 治疗超过16年后ADR估算比例:NNRTI 29%、3TC/FTC 28%、其他nRTI 14%、PI 7%。
- 2011-2014年启动cART者ADR罕见,主要见于依从性<40%者。
核心结论
- HIV耐药从主要由治疗新选择驱动转变为由传播性耐药驱动,近期启动治疗者ADR罕见且集中于低依从性层。
主要发现
- ADR比例从1996年39%(51/132)降至2014年3%(8/322),p<0.0001。
- TDR比例从1996年12%(16/132)升至2014年18%(59/322),p=0.14。
- 治疗超过16年后ADR估算比例:NNRTI 29%、3TC/FTC 28%、其他nRTI 14%、PI 7%。
- 治疗5年后,1996-2000年启动者较2011-2014年启动者3TC/FTC ADR高5.5倍、其他nRTI高5.3倍、NNRTI高4.7倍、PI高24倍。
关键数值与推荐
- 耐药突变按IAS-USA 2015列表定义。
- 1996-2010年启动cART者ADR最高比值比见于依从性60%-80%者,2011-2014年则移至依从性<40%者。
临床怎么用
- 对近期启动cART者应重点监测低依从性人群的ADR风险。
- 传播性耐药比例上升提示治疗前耐药检测仍需重视。
局限性
- TDR比例变化无统计学意义(p=0.14)。
- ADR估算基于Kaplan-Meier法,长期数据受随访时间影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aim to identify long-term trends in HIV drug resistance before and after combined antiretroviral therapy (cART) initiation. METHODS: IAS-USA (2015) mutations were identified in 23 271 HIV protease-reverse transcriptase sequences from 6543 treatment naïve adults in British Columbia. Participants who started cART between 1996 and 2014 were followed until April 2016. Equality of proportions test was used to compare the percentage of participants with acquired drug resistance (ADR) or transmitted drug resistance (TDR) in 1996, to those in 2014. Kaplan-Meier was used to estimate time to ADR in four drug resistance categories. Multivariable regression odds ratios (OR) of ADR for select clinical variables were determined by 5-year eras of cART initiation. RESULTS: The proportion of individuals with ADR declined from 39% (51/132) to 3% (8/322) in 1996-2014 (p <0.0001), while the proportion with TDR increased from 12% (16/132) to 18% (59/322) (p 0.14). The estimated proportions of individuals with ADR rose to 29% (NNRTI), 28% (3TC/FTC), 14% (other nRTI), and 7% (PI) after >16 years of therapy. After 5 years on therapy, participants initiating cART in 1996-2000 had 5.5-times more 3TC/FTC ADR, 5.3-times more other nRTI ADR, 4.7-times more NNRTI ADR, and 24-times more PI ADR than those starting in 2011-2014. The individuals with highest odds of developing ADR in 1996-2010 were adherent to regimens at levels between 60% and 80%, which shifted to <40% adherent in 2011-2014. CONCLUSIONS: HIV drug resistance transitioned from being primarily selected de-novo to being driven by TDR. Among those who started treatment in the past 5 years, ADR is rare and observed mostly in the lowest adherence strata.
引用
- Rocheleau G, Brumme CJ, Shoveller J, et al. Longitudinal trends of HIV drug resistance in a large Canadian cohort, 1996-2016. Clin Microbiol Infect. 2017. PMID: 28652115. doi:10.1016/j.cmi.2017.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。